D. James Ballance

Ceptur Therapeutics, Inc. is a company that focuses on developing medicines for severe diseases in the areas of oncology, the central nervous system, nephrology, and immunology. The company is based in Hillsborough, NJ and has subsidiaries in the United States. The company is revolutionizing RNA therapeutics with U1 adaptor technology to address unaddressed diseases. The company was founded by Rafal Goraczniak and P. Peter Ghoroghchian, with P. Peter Ghoroghchian serving as CEO since incorporation.

Apple Tree venture Managemnet LLC (Apple Tree Partners) is a venture capital firm founded by Seth Harrison in 1999. The firm is headquartered in New York with an additional offices in London, San Francisco and Cambridge.

Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA.

Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million.

Limelight Bio, Inc. engages in the development of proprietary technologies, advanced targets, and drug candidates for the expansion of current gene therapy and gene editing approaches. The company was founded by Phil Johnson and Jean Bennett in 2017 and is headquartered in Philadelphia, PA.

Marengo Therapeutics, Inc. operates as a biotechnology company that develops immunotherapies. Its product is Universal Targeted Immunotherapy a drug discovery platform that underpins an immunological tumor elimination. The company was founded by Andreas Loew and is headquartered in Cambridge, MA.

Part of Rothschild & Co. The company is based in New York, NY. Continuation Holdings AG, Rothschild, Inc. provides investment banking and advisory services.

Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London.

Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA.

Braeburn Pharmaceuticals SPRL develops and commercializes medical products. It’s a pharmaceutical company focused on novel, long-acting implantable and injectable therapies for serious neurological and psychiatric disorders, including addiction, pain, and schizophrenia. The firm offers Probuohine, CAM2038q1w, CAM2038q4w and Risperdone implant. The company was founded in 2012 and is headquartered in Road Town, British Virgin Islands.